Cigna rated 'Buy' after strong Q1 2026, with 15% annual returns expected through 2031.

Cigna Group is reaffirmed as a 'Buy' due to strong first-quarter 2026 results, raised guidance, and ongoing business momentum. Growth is driven by its pharmacy and behavioral health segments, although divestitures and pharmacy benefit manager reforms slightly temper 2026 earnings. The stock trades at a 25% discount to a $377 fair value estimate, suggesting potential 15% annual total returns through 2031. Cigna's solid balance sheet, leading dividend coverage, and growth opportunities in biosimilars and behavioral health support this positive outlook.